

March 27, 2013



## **Boston Therapeutics Strategically Positioned to Focus Its Pipeline on Commercializing Pharmaceutical Drugs to Treat Diabetes and Inflammatory Disease: To Accelerate Commercialization of PAZ320 & IPOXYN(TM)**

MANCHESTER, NH -- (MARKETWIRE) -- 03/27/13 -- Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a pharmaceutical company focused on developing and commercializing complex carbohydrate-based drugs to treat diabetes and inflammatory diseases, today announced it will focus its pipeline to accelerate the commercialization of PAZ320 and IPOXYN™.

"We are a drug discovery, development and commercialization Company. Our focus on PAZ320 and IPOXYN™ will enable the Company to further advance its status as a premier developer of complex carbohydrate-based new chemical entities," said David Platt, Ph.D., Chief Executive Officer of Boston Therapeutics. "We are particularly excited about the progress we are making with PAZ320, which we believe will offer an exciting alternative to current treatment options for people with diabetes to better manage their post-prandial glucose (PPG) or post-meal blood sugar. We also plan to accelerate the commercialization of IPOXYN™, an anti-necrosis drug that targets both human and animal tissue and organ systems deprived of oxygen and in need of metabolic support. IPOXYN™ was specifically developed to treat lower limb ischemia associated with diabetes."

Earlier this year, the Company reported positive results on a Phase II clinical trial evaluating the safety and efficacy of PAZ320, a complex carbohydrate-based drug designed to reduce the elevation of PPG by blocking the action of carbohydrate-hydrolyzing enzymes that digest carbohydrates in food. Patients with type 2 diabetes responded with a 40 percent reduction of PPG in the blood compared to baseline in a dose-dependent manner. Additionally, results showed the effect of PAZ320 does not correlate with duration of diabetes and works regardless of concurrent diabetes medications. There was no severe hypoglycemia and gastrointestinal side effects were mild. Satiety also was observed. There were no serious adverse events from the data analysis of the open-label dose escalation crossover trial.

The study evaluated the combination of PAZ320 and oral agents or insulin in 24 patients with type 2 diabetes between the ages of 18 and 75 with a body mass index (BMI) of 25-40 kg/m<sup>2</sup> and with HbA1c of less than or equal to nine percent. HbA1c is a lab test that shows the average level of blood sugar (glucose) over the previous three months.

The abstract for the clinical study is published in Epub ahead of print in PubMed website

<http://www.ncbi.nlm.nih.gov/pubmed/23425645> and the full article is expected to be published in the July/August issue of *Endocrine Practice*, a peer-reviewed journal.

### **About PAZ320**

PAZ320 is a non-systemic chewable complex carbohydrate-based compound designed to mimic insulin and reduce the elevation of post-prandial glucose (PPG) or post-meal blood sugar. PAZ320 is a proprietary polysaccharide designed to be taken before meals and works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down carbohydrates into glucose and release it into the bloodstream.

### **About IPOXYN**

IPOXYN is a glycoprotein anti-necrosis drug candidate, specifically developed for Lower Limb Ischemia associated with diabetes.

### **About Boston Therapeutics, Inc.**

Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is a leader in the field of complex carbohydrate chemistry. The Company's product pipeline is focused on developing and commercializing therapeutic molecules for diabetes, including PAZ320, a non-systemic chewable therapeutic compound designed to reduce the elevation of post-prandial glucose (PPG) or post-meal blood sugar, and IPOXYN™, an injectable anti-necrosis drug specifically designed to treat lower limb ischemia associated with diabetes. More information is available at [www.bostonti.com](http://www.bostonti.com).

### **Forward Looking Statements**

Any statements in this news release about future expectations, plans and prospects for the Company constitute forward-looking statements as defined in the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in such statements.

More information about those risks and uncertainties is contained and discussed in the Company's most recent quarterly or annual report and in the Company's other reports filed with the Securities and Exchange Commission. The forward-looking statements represent the Company's views as of the date of this news release and should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.

### **Contact:**

Boston Therapeutics, Inc.  
Anthony Squeglia  
Director of Strategic Planning  
Phone: 603-935-9799  
Email: [anthony.squeglia@bostonti.com](mailto:anthony.squeglia@bostonti.com)

